Marcaine 0,5 % Adrénaline (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state and preventing the initiation and propagation of nerve impulses. This interruption of signal transmission results in loss of sensation in the targeted area, producing the anesthetic effect.

The specific dose of Marcaine 0,5 % Adrénaline is determined by the prescribing clinician based on the type of procedure, patient weight, age, and overall health. Healthcare professionals calculate the appropriate volume to stay within safe maximum limits for bupivacaine.

Safety data for Marcaine 0,5 % Adrénaline in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative anesthetic options when treating pregnant or nursing patients.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Marcaine (bupivacaine with epinephrine) provides a longer duration of anesthesia than lidocaine, which is shorter‑acting. The added epinephrine in Marcaine reduces systemic absorption, further extending the block, whereas lidocaine typically lacks this vasoconstrictive component.

Store the solution at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct light and moisture. Do not freeze the product, and ensure the container is tightly sealed to maintain sterility.

The medication is administered by a qualified healthcare professional via injection. It can be delivered epidurally for spinal analgesia, infiltrated directly into tissue for localized numbness, or used for peripheral nerve blocks, depending on the clinical indication.

Serious risks include cardiac arrhythmias, seizures, severe hypotension, and anaphylactic reactions. These events are rare but require immediate medical attention. Monitoring of cardiovascular status and adherence to maximum dosage limits are essential to minimize these risks.

Patients with known hypersensitivity to bupivacaine, epinephrine, or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with uncontrolled hypertension, certain cardiac conduction disorders, or those taking MAO inhibitors without careful supervision.